# US 2025/0025506 A1 · Engineered safety in cell therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0025506 A1
- Document ID: US20250025506A1
- Status: Published application
- Kind: A1
- Application number: 18/819,922
- Filed: 2024-08-29
- Published: 2025-01-23
- Earliest claimed: 2020-02-19
- Assignees: Innovative Cellular Therapeutics Holdings, Ltd.; Innovative Cellular Therapeutics, Inc.
- Applicants: Innovative Cellular Therapeutics Holdings, Ltd.; Innovative Cellular Therapeutics, Inc.
- Inventors: Chengfei Pu; Zhiyuan Cao; Zhao Wu; Lei Xiao
- Web page: https://patentgrep.com/patent/US20250025506A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/42: Cancer antigens
- A61K 40/4211: {CD19 or B4}
- A61P 35/00: Antineoplastic agents
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/5412: {IL-6}
- C07K 14/5418: {IL-7}
- C07K 14/5434: {IL-12}
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/57: IFN-gamma
- A61K 2039/55538: {IL-12}
- A61K 2039/868: {kidney}
- A61K 2239/58: Prostate
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to compositions and methods for treating cancer. For example, a modified cell may include a polynucleotide comprising an NFAT promoter, a nucleotide sequence encoding therapeutic agent, and a nucleotide sequence encoding a VHL-interaction domain of HIF1α, wherein the therapeutic agent comprises, for example, IL-12, IL-6, and/or IFNγ.

## Claims

### Claim 1

A method for modifying a population of immune cells, the method comprising: contacting the population of immunocytes with a mixture of lentiviral vectors, thereby obtaining the modified immunocytes, wherein the mixture of lentiviral vectors comprises:
a first vector encoding a CAR targeting a solid tumor antigen;
a second vector encoding a CAR targeting a white blood cell antigen and IL6;
a third lentiviral vector encoding a CAR targeting the white blood cell antigen and IFNγ; and
a fourth lentiviral vector encoding a CAR targeting the white blood cell antigen and IL12.

### Claim 2 (depends on 1)

The method of claim 1, wherein the CAR comprises an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.

### Claim 3 (depends on 2)

The method of claim 2, wherein the antigen-binding domain binds one or more of the following tumor antigens: GUCY2C (GCC), TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvlll, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, Mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, CD20, Folate receptor alpha, ERBB2 (Her2/neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, Fucosyl GM1, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, legumain, HPV E6, E7, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin, telomerase, PCTA-1 (Galectin 8), MelanA (MART1), Ras mutant, ML-IAP, ERG (TMPRSS2 ETS fusion partner), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1.

### Claim 4 (depends on 2)

The method of claim 2, wherein the intracellular signaling domain comprises a co-stimulatory signaling domain comprising a functional signaling domain of at least one of CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, CD4,CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG (Cbp), NKp44, NKp30, NKp46, and NKG2D.

### Claim 5 (depends on 1)

The method of claim 1, wherein the immune cells are T cells or NK cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein the immune cells are T cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the white blood cell antigen is CD19, CD22, CD20, BCMA, CD5, CD7, CD2, CD16, CD56, CD30, CD14, CD68, CD11b, CD18, CD169, CD1c, CD33, CD38, CD138, or CD13.

### Claim 8 (depends on 1)

The method of claim 1, wherein the white blood cell antigen is CD205, CD19, CD20, CD22, or BCMA.

### Claim 9 (depends on 1)

The method of claim 1, wherein the white blood cell antigen is CD19.

### Claim 10 (depends on 1)

The method of claim 1, wherein the nucleotide sequence encoding IL12, IL6, or IFNγ is flanked by a nuclear factor of activated T-cells (NFAT) promoter and a nucleotide sequence encoding a VHL-interaction domain of hypoxia-inducible factor 1-alpha (HIF1α).

### Claim 11 (depends on 1)

The method of claim 1, wherein the solid tumor antigen is GUCY2C (GCC).

### Claim 12 (depends on 1)

The method of claim 1, wherein the CARs are introduced into the T cells via lentiviral transduction.

### Claim 13 (depends on 1)

The method of claim 1, wherein the population of immune cells are in a subject and the subject is a human patient diagnosed with a cancer expressing the targeted antigens.

### Claim 14 (depends on 12)

The method of claim 12, wherein the transduction efficiency is optimized by using one or more multiplicity of infections (MOI) for vectors.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the population of immune cells produced by the method of claim 1 and a pharmaceutically acceptable carrier, wherein the immune cells are modified T cells.

### Claim 16

A mixture of lentiviral vectors for modifying a population of immunocytes to express chimeric antigen receptors (CARs), wherein the mixture comprises:
a first lentiviral vector encoding a CAR targeting a solid tumor antigen;
a second lentiviral vector encoding a CAR targeting a white blood cell antigen and IL6;
a third lentiviral vector encoding a CAR targeting a white blood cell antigen and IFNγ; and
a fourth lentiviral vector encoding a CAR targeting a white blood cell antigen and IL12.

### Claim 17 (depends on 16)

The mixture of lentiviral vectors of claim 16, wherein the CAR comprises an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.

### Claim 18 (depends on 17)

The mixture of lentiviral vectors of claim 17, wherein the antigen-binding domain binds one or more of the following tumor antigens: GUCY2C (GCC), TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvlll, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, Mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, CD20, Folate receptor alpha, ERBB2 (Her2/neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, Fucosyl GM1, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97,CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, legumain, HPV E6, E7, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin, telomerase, PCTA-1 (Galectin 8), MelanA (MART1), Ras mutant, ML-IAP, ERG (TMPRSS2 ETS fusion partner), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1.

### Claim 19 (depends on 16)

The mixture of lentiviral vectors of claim 16, wherein the immune cells are T cells.

### Claim 20 (depends on 16)

The mixture of lentiviral vectors of claim 16, wherein the white blood cell antigen is CD205, CD19, CD20, CD22, or BCMA.
